Nika Pharmaceuticals, Inc 8-K, filed Oct 1, 2024
Nika Pharmaceuticals, Inc (NIKA)
About this 8-K
Nika Pharmaceuticals, Inc filed this 8-K on October 1, 2024, reporting on events of September 23, 2024.
Items reported
- Item 4.01: Change of auditor
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 1, 2024
(
(Exact
Name of Registrant as Specified in Charter)
| |
| |
| (State or other jurisdiction of Nika Pharmaceuticals, Inc.) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip code)
(
Registrant's telephone number, including area
code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Section 4 - Matters Related to Accountants and Financial Statements
Item 4.01 Changes in Registrant’s Certifying Accountant.
On September 23, 2024, Nika Pharmaceuticals, Inc. engaged the firm of OLAYINKA OYEBOLA & CO (Chartered Accountants) to serve as the independent accountant to audit the company’s financial statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.
| NIKA PHARMACEUTICALS, INC. | ||
| Dated: October 1, 2024 | By: | /s/ Dimitar Slavchev Savov |
| Dimitar Slavchev Savov | ||
| Chief Executive Officer, | ||
| Director | ||